Protagenic Therapeutics, Inc.\new (PTIX) - Dilution Analysis

10-Q filing | 1.9M shares outstanding

10-Q filing | 1.8M shares outstanding

8-K filing: Protagenic Therapeutics, Inc. authorized a distribution of rights to purchase shares of common stock to stockholders of record as of July 7, 2025, with each right entitling the holder to purchase 4.57 shares of common stock at $0.01 per share, subject to stockholder approval of the Proposed Transactions.

8-K filing: Protagenic Therapeutics entered into a Warrant Exchange Agreement with an unaffiliated third party investor to exchange 459,420 warrants for 367,544 shares of common stock.

8-K filing: Protagenic Therapeutics, Inc. acquired 100% of Phytanix Bio by issuing common stock, Series C Convertible Preferred Stock, Series C-1 Convertible Preferred Stock, Series D Preferred Stock, and common stock purchase warrants.

10-Q filing | 0.6M shares outstanding

8-K filing: Stock split 1-for-14 | Outstanding: 7,525,681 → 537,548

10-K filing | 7.5M shares outstanding

S-3/A filing: This S-3/A filing registers unsold securities from a prior registration statement (File No. 333-256790) and includes new securities for future offerings, particularly an at-the-market offering of common stock through B. Riley Securities and E.F. Hutton. The offering period extends until the earlier of the new registration statement's effective date or December 20, 2024.

S-1 filing: The filing relates to the registration of 5,844,885 shares of common stock for resale by selling stockholders. The company will not receive any proceeds from the sale of these shares, but may receive proceeds from the exercise of common stock warrants.

10-Q filing | 6.8M shares outstanding

8-K filing: The Company closed a transaction on November 4, 2024, selling 1,948,295 shares of common stock, series A warrants to purchase 1,948,295 shares, and series B warrants to purchase 1,948,295 shares for gross proceeds of approximately $1.275 million. ($1.28M proceeds)

8-K filing: Protagenic Therapeutics, Inc. entered into a Securities Purchase Agreement with institutional investors to issue 1,948,295 shares of common stock and warrants to purchase additional shares at $0.64 per share, with gross proceeds of approximately $1.275 million. ($1.28M proceeds)

10-Q filing | 4.4M shares outstanding

S-3 filing: The company filed an S-3 form to offer and sell up to $100,000,000 of any combination of common stock, preferred stock, debt securities, warrants, or units.

10-Q filing | 4.4M shares outstanding

10-K filing | 4.3M shares outstanding

10-Q filing | 4.3M shares outstanding

10-Q filing | 4.3M shares outstanding

10-Q filing | 4.3M shares outstanding

10-K filing | 4.3M shares outstanding

8-K filing: Stock split 1-for-4 | Outstanding: 17,285,261 → 4,321,315

10-Q filing | 17.3M shares outstanding

10-Q filing | 17.3M shares outstanding

10-Q filing | 17.2M shares outstanding

10-K filing | 17.3M shares outstanding

10-Q filing | 17.0M shares outstanding

S-3/A filing: This prospectus relates to the offer and sale of 7,221,607 shares of common stock par value $0.0001 per share for the account of the selling stockholders named in this prospectus.

10-Q filing | 16.7M shares outstanding

S-3 filing: This prospectus relates to the offer and sale of 6,801,607 shares of common stock par value $0.0001 per share for the account of the selling stockholders named in this prospectus.

S-3/A filing: This is an S-3/A filing to register additional securities for an offering.

S-3 filing: The filing is an S-3 form registering an indeterminate number of shares of common stock and preferred stock, such indeterminate depositary shares representing preferred stock, such indeterminate principal amount of debt securities, and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities as may be sold by the Registrant from time to time, which together shall have an aggregate initial offering price not to exceed $100,000,000.

10-Q filing | 10.4M shares outstanding

8-K filing: Protagenic Therapeutics, Inc. entered into an underwriting agreement with Kingswood Capital Markets to issue and sell 3,180,000 shares of common stock and warrants to purchase 3,180,000 shares of common stock at a price of $4.15 per share, resulting in net proceeds of approximately $11.4 million. ($13.3M proceeds)

S-1/A filing: Protagenic Therapeutics, Inc. is offering 2,650,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

S-1/A filing: Protagenic Therapeutics, Inc. is offering 2,650,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.

S-1/A filing: S-1/A filing for Protagenic Therapeutics, Inc. outlining the offering of 2,650,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.

S-1/A filing: This S-1/A filing registers common stock and warrants for listing on The Nasdaq Capital Market.

S-1/A filing: This S-1/A filing describes an offering of units, each consisting of one share of common stock and one warrant to purchase one-half share of common stock. The company intends to use the net proceeds for clinical trials, key hires, development expenses, working capital and general corporate purposes.

10-K filing | 10.3M shares outstanding

10-Q filing | 10.4M shares outstanding

8-K filing: Protagenic Therapeutics, Inc. issued and sold $427,500 aggregate principal amount of unsecured convertible promissory notes to accredited investors on August 28, 2020.

10-Q filing | 10.3M shares outstanding

8-K filing: Protagenic Therapeutics, Inc. issued unsecured convertible promissory notes to accredited investors in the aggregate principal amount of $475,000.

10-Q filing | 10.3M shares outstanding

8-K filing: Protagenic Therapeutics, Inc. completed the Fourth Closing of a private offering, issuing convertible promissory notes to accredited investors for an aggregate principal amount of $145,000, with a conversion price of $1.25 per share. Additionally, the Placement Agent received warrants to purchase 18,400 shares of common stock at an exercise price of $1.25 per share as compensation for funds raised.

10-K filing | 10.3M shares outstanding

8-K filing: Protagenic Therapeutics, Inc. issued unsecured convertible promissory notes to accredited investors for $230,000 in the Fourth Closing of a private offering, with the potential to issue up to $2,500,000 in total. The Placement Agent received warrants to purchase 18,400 shares of Common Stock at an exercise price of $1.25 per share as compensation.